ReniBenjamin
Okay. And then I guess just turning to the commercialization side. Can you just remind me, have you guys already identified the centers or the community docs that you will be targeting right off the bat? Or how should we be thinking about the initial phases of the launch?
AdamCraig
Bruce will answer.
BruceSeeley
The -- in initial launch were not surprising any target, the high volume accounts in the academic centers, and then we've identified also the large community accounts that treat quite a few patients, the group practice or the large group practices. And that's where the far majority of the patients are treated.
ReniBenjamin
And Bruce, about how many, could you give us like how many accounts are there from academic versus community?
BruceSeeley
It depends on how you look at it. Just in terms of number of physicians, the majority of physicians are going to be in the community accounts. They treat anywhere from 0, 1 or 2 patients to 5-ish patients. The large practices are the ones that we're going to be focused on. And the academic centers we're focused on, they can treat 20 to 50 patients per year depending on the site.
Operator
Your next question is from Thomas Flaten of Lake Street Capital.
ThomasFlaten
Adam, how do you -- how should we think about PACIFICA enrollment once you guys go live commercially? Do you see there being some cannibalization there or have you -- do you have a strategy for segregating patients in the study versus commercial product?
AdamCraig
Thank you. Its a very important question. The - its most likely that PACIFICA will continue ex-U.S. after approval. And we are no doubt towards the end of the NDA process where we'll have some discussions with the FDA around the program -- around that trial with maybe some changes to it. But big picture, I don't expect that to be cannibalization of U.S. sales opportunities. The drug is performing very well ex-U.S. at the moment, and I think we could successfully complete the trial outside the U.S. on time.
